Merck & Co (MRK)
$126.45
0.60 (0.48%)
MRK Stock Quote Delayed 30 Minutes
Stocks Push Forward As Fears of War Diminish
Stocks climbed again on Monday, shrugging off the U.S.-led airstrike on Syria over the weekend. Now the market will get an update on U.S. industrial production as well as a batch of Federal Reserve policymaker speeches.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
320.09B
PE Ratio
140.50
EPS
0.9
Volume (Avg. Vol.)
6.79M
Day's Range
$124.91 - $126.60
52-Week Range
$99.14 - $134.63
Dividend & Yield
$2.92 (2.31%)
MRK Stock Predictions, Articles, and Merck & Co News
Incyte Corporation Stock Plunges on Melanoma Drug Trial Failure
Incyte (INCY) was falling hard on Friday following news of a failed Phase 3 drug trial for its melanoma drug epacadostat.
4 Dow Jones Heavyweights That Are Still on the Ropes
Some headwinds are appearing now, and with trading liquidity still very light, the machines are feeding some selling pressure at current levels. Here are four Dow Jones stocks that could see some trouble as a result.
The Future of Merck & Co., Inc. Stock Is With Keytruda
Merck & Co's cancer drug, Keytruda, saw explosive growth this quarter, making MRK stock a tough name to handicap right now.
Why Investors Should Stay Long Eli Lilly and Co Stock
LLY stock had a sudden drop on Jan. 22, but Eli Lilly and Co recovered the bulk of its losses, which means bulls can stay long for the time being.
Merck & Co., Inc.’s Rally Could Burn Investors
While Merck is riding high on good news from Keynote-189, there's still too much danger to make MRK stock a strong buy.
Adverse Earnings Momentum Make Merck & Co (MRK) a Sell
Merck & Co (NYSE:MRK) is one of the 657 companies in the GICS Health Technology sector, and a component of the 38 company Pharmaceuticals: Major GICS industry group within this sector. MRK has a market value of $159.9 billion which is in the top quarter of its industry group. The stock's current Portfolio Grader ranking places it 38 among the 38 companies in this industry group, a position that is well below-average; squarely in the bottom quartile of the sector with a ranking of 577 among the 657 companies in the sector, and number 4,121 in the nearly 5,000 company Portfolio Grader universe.
Merck & Co., Inc. Stock Could Still Soar Another 10% From Here
Positive Keytruda results have propelled Merck higher over the last week. Buying a pullback is the prudent play for investors in MRK stock.
Merck & Co., Inc. (MRK) Stock Surges on Lung Cancer Drug Success
Merck (MRK) shares were surging Tuesday as the company's latest lung cancer drug yielded positive results, helping patients live longer.
After Irrational Fire Sale, It’s Time to Buy the Dip in Merck & Co., Inc. Stock
Merck is struggling after a supposedly disappointing earnings report, but the resultant selloff in Merck stock is well overdone.
Merck & Co (MRK) a Sell on Adverse Earnings Momentum
Portfolio Grader currently ranks Merck & Co (NYSE:MRK) a Sell. The methodology for fundamental and quantitative metrics used in this analytical tool, developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week. MRK has maintained this ranking for 2 months.
Walt Disney Co Leads 5 Dividend Stocks Boosting Payouts
Five notable dividend stocks recently raised their payouts, including Walt Disney (DIS). Here's what you need to know about each.
Merck & Co (MRK) a Sell on Lousy Sales Growth
The current recommendation of Sell for Merck & Co (NYSE:MRK) is derived using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing system. This represents no change from the previous week and is the same ranking MRK has had from Portfolio Grader for the last month.
Analytics for Quant Score Make Merck & Co (MRK) a Sell
Merck & Co (NYSE:MRK) is one of 133 companies within the Pharmaceuticals GICS industry group, which is in turn part of the 781 company GICS Health Care sector. MRK's market value is $150.5 billion which falls in the top 10% of its industry group. The stock's current Portfolio Grader ranking places it 120 among the 133 companies in this industry group, a position that is well below-average; squarely in the bottom quartile of the sector with a ranking of 679 among the 781 companies in the sector, and number 4,148 in the nearly 5,000 company Portfolio Grader universe.
Bet on Biogen Inc for Easy Profits Into the New Year
Biotech stocks are scary when they are falling. Sell downside risk into BIIB stock support with confidence for a chance at free profits.
Merck & Co., Inc. Stock’s Decline Is a Reason to Get In Now
Merck stock is a tempting contrarian play. Here's why investors should consider picking up MRK stock at its current discount.
